JP6970115B2 - デングウイルス複製阻害剤としての置換インドリン誘導体 - Google Patents

デングウイルス複製阻害剤としての置換インドリン誘導体 Download PDF

Info

Publication number
JP6970115B2
JP6970115B2 JP2018550545A JP2018550545A JP6970115B2 JP 6970115 B2 JP6970115 B2 JP 6970115B2 JP 2018550545 A JP2018550545 A JP 2018550545A JP 2018550545 A JP2018550545 A JP 2018550545A JP 6970115 B2 JP6970115 B2 JP 6970115B2
Authority
JP
Japan
Prior art keywords
compound
mmol
reduced pressure
under reduced
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018550545A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510034A (ja
JP2019510034A5 (enExample
Inventor
ルドルフ ロマニー ケステルイン，バート
ジャン−マリー ベルナール ラボワッソン，ピエール
ボンファンティ，ジャン−フランソワ
アリス マリー−イヴ バルディオ，ドロセー
ディディエ エム． マーチャン，アルノー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Publication of JP2019510034A publication Critical patent/JP2019510034A/ja
Publication of JP2019510034A5 publication Critical patent/JP2019510034A5/ja
Application granted granted Critical
Publication of JP6970115B2 publication Critical patent/JP6970115B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018550545A 2016-04-01 2017-03-31 デングウイルス複製阻害剤としての置換インドリン誘導体 Active JP6970115B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16163488.6 2016-04-01
EP16163488 2016-04-01
PCT/EP2017/057661 WO2017167951A1 (en) 2016-04-01 2017-03-31 Substituted indoline derivatives as dengue viral replication inhibitors

Publications (3)

Publication Number Publication Date
JP2019510034A JP2019510034A (ja) 2019-04-11
JP2019510034A5 JP2019510034A5 (enExample) 2020-04-23
JP6970115B2 true JP6970115B2 (ja) 2021-11-24

Family

ID=55650311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018550545A Active JP6970115B2 (ja) 2016-04-01 2017-03-31 デングウイルス複製阻害剤としての置換インドリン誘導体

Country Status (31)

Country Link
US (2) US10689340B2 (enExample)
EP (1) EP3436437B1 (enExample)
JP (1) JP6970115B2 (enExample)
KR (1) KR102359776B1 (enExample)
CN (1) CN108884037B (enExample)
AR (1) AR108046A1 (enExample)
AU (1) AU2017242894B2 (enExample)
CA (1) CA3013406C (enExample)
CL (1) CL2018002758A1 (enExample)
CO (1) CO2018009563A2 (enExample)
CR (1) CR20180493A (enExample)
DK (1) DK3436437T3 (enExample)
EA (1) EA037988B1 (enExample)
EC (1) ECSP18073293A (enExample)
ES (1) ES2884067T3 (enExample)
HR (1) HRP20211278T1 (enExample)
HU (1) HUE055577T2 (enExample)
IL (1) IL261948B (enExample)
JO (1) JOP20170069B1 (enExample)
LT (1) LT3436437T (enExample)
MX (1) MX381634B (enExample)
MY (1) MY195194A (enExample)
PE (1) PE20181778A1 (enExample)
PH (1) PH12018502077A1 (enExample)
SG (1) SG11201808409XA (enExample)
SI (1) SI3436437T1 (enExample)
TW (1) TWI723148B (enExample)
UA (1) UA125296C2 (enExample)
UY (1) UY37182A (enExample)
WO (1) WO2017167951A1 (enExample)
ZA (1) ZA201806482B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020520950A (ja) * 2017-05-22 2020-07-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
HUE054936T2 (hu) 2016-03-31 2021-10-28 Janssen Pharmaceuticals Inc Helyettesített indol-származékok mint a dengue-vírus replikációjának inhibitorai
CA3013407A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3436004B1 (en) 2016-04-01 2024-12-11 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201992782A1 (ru) * 2017-05-22 2020-03-24 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
IL292970A (en) 2019-11-15 2022-07-01 Janssen Pharmaceuticals Inc Treatment and prevention of dengue disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1200899A (en) 1997-10-27 1999-05-17 Eli Lilly And Company Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
AU2002364566B2 (en) 2001-12-12 2009-03-26 Conforma Therapeutics Corporation Assays and implements for determining and modulating HSP90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
CA2593450A1 (en) 2005-01-14 2006-07-20 Genelabs Technologies, Inc. Indole derivatives for treating viral infections
US20060194835A1 (en) 2005-02-09 2006-08-31 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
US9029376B2 (en) 2008-06-03 2015-05-12 Siga Technologies, Inc. Small molecule inhibitors for the treatment or prevention of dengue virus infection
JP5559174B2 (ja) * 2008-08-19 2014-07-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 冷感−メントール受容体拮抗剤
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
WO2011088303A1 (en) 2010-01-15 2011-07-21 Gilead Sciences , Inc. Inhibitors of flaviviridae viruses
EP2552211A4 (en) 2010-03-26 2013-10-23 Glaxo Group Ltd INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) * 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
DK3060547T3 (en) 2013-10-23 2018-01-15 Janssen Sciences Ireland Uc CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B
UY35971A (es) 2014-01-31 2015-07-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
BR112017006299A2 (pt) 2014-10-01 2018-01-16 Janssen Pharmaceuticals, Inc. derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
ME03344B (me) * 2014-10-01 2019-10-20 Janssen Pharmaceuticals Inc Mono- ili di-supstituisani indoli kao inнibitori replikacije denga virusa
NO2721243T3 (enExample) 2014-10-01 2018-10-20
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN108601723B (zh) 2015-11-03 2022-05-17 硕腾服务有限责任公司 溶胶-凝胶聚合物复合材料及其用途
SG11201807539UA (en) 2016-03-31 2018-09-27 Takeda Pharmaceuticals Co Heterocyclic compound
CA3013407A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
HUE054936T2 (hu) 2016-03-31 2021-10-28 Janssen Pharmaceuticals Inc Helyettesített indol-származékok mint a dengue-vírus replikációjának inhibitorai
CN109069512B (zh) 2016-04-01 2022-06-14 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物以及相关治疗方法
KR20210089262A (ko) 2016-04-01 2021-07-15 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
KR102411744B1 (ko) 2016-04-01 2022-06-21 바스프 에스이 바이시클릭 화합물
EP3436004B1 (en) 2016-04-01 2024-12-11 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201808411RA (en) 2016-04-01 2018-10-30 Kite Pharma Inc Chimeric antigen and t cell receptors and methods of use
UA128326C2 (uk) 2016-04-01 2024-06-12 Амджен Інк. Химерний рецептор до flt3 та спосіб його застосування
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201992782A1 (ru) 2017-05-22 2020-03-24 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA039702B1 (ru) 2017-05-22 2022-03-01 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020520950A (ja) * 2017-05-22 2020-07-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体
JP7179773B2 (ja) 2017-05-22 2022-11-29 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体

Also Published As

Publication number Publication date
JP2019510034A (ja) 2019-04-11
UA125296C2 (uk) 2022-02-16
HUE055577T2 (hu) 2021-12-28
MX2018011785A (es) 2019-02-13
KR102359776B1 (ko) 2022-02-07
EA037988B1 (ru) 2021-06-21
SI3436437T1 (sl) 2021-11-30
AU2017242894B2 (en) 2021-07-29
TW201808898A (zh) 2018-03-16
BR112018068640A2 (pt) 2019-07-30
EA201892219A1 (ru) 2019-03-29
PH12018502077A1 (en) 2019-07-15
IL261948B (en) 2021-07-29
KR20180132661A (ko) 2018-12-12
CA3013406C (en) 2024-01-09
ZA201806482B (en) 2021-04-28
ES2884067T3 (es) 2021-12-10
WO2017167951A1 (en) 2017-10-05
CL2018002758A1 (es) 2018-11-23
AU2017242894A1 (en) 2018-08-09
US11180450B2 (en) 2021-11-23
LT3436437T (lt) 2021-08-25
UY37182A (es) 2017-09-29
TWI723148B (zh) 2021-04-01
JOP20170069B1 (ar) 2021-08-17
EP3436437A1 (en) 2019-02-06
US20200299235A1 (en) 2020-09-24
AR108046A1 (es) 2018-07-11
CN108884037A (zh) 2018-11-23
EP3436437B1 (en) 2021-05-19
US10689340B2 (en) 2020-06-23
SG11201808409XA (en) 2018-10-30
CA3013406A1 (en) 2017-10-05
US20190112266A1 (en) 2019-04-18
ECSP18073293A (es) 2018-10-31
IL261948A (en) 2018-10-31
MX381634B (es) 2025-03-12
CR20180493A (es) 2018-12-06
MY195194A (en) 2023-01-11
DK3436437T3 (da) 2021-08-09
PE20181778A1 (es) 2018-11-05
HRP20211278T1 (hr) 2022-01-21
CO2018009563A2 (es) 2018-09-20
CN108884037B (zh) 2021-05-04

Similar Documents

Publication Publication Date Title
JP6970115B2 (ja) デングウイルス複製阻害剤としての置換インドリン誘導体
JP6931357B2 (ja) デングウイルス複製阻害剤としての置換インドリン誘導体
JP7038733B2 (ja) デングウイルス複製阻害剤としての置換インドリン誘導体
JP7203752B2 (ja) デングウイルス複製阻害剤としての置換インドリン誘導体
JP6888021B2 (ja) デングウイルス複製阻害剤としての置換インドール誘導体
JP7007290B2 (ja) デングウイルス複製阻害剤としての置換インドール化合物誘導体
JP2021193092A (ja) デングウイルス複製阻害剤としての一または二置換インドール誘導体
JP2021181485A (ja) デングウイルス複製阻害剤としての一または二置換インドール誘導体
KR20180002644A (ko) 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체
KR20170063802A (ko) 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체
HK1260482A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
HK1260967B (en) Substituted indoline derivatives as dengue viral replication inhibitors
HK1260482B (zh) 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200316

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211028

R150 Certificate of patent or registration of utility model

Ref document number: 6970115

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250